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Gastric cancer is the most common cancer worldwide. The 
proportion of early gastric cancer (EGC) cases at diagnosis 
has increased because of the use of mass screening endos-
copy in older adults. Endoscopic mucosal resection has be-
come the standard treatment for EGC in cases with standard 
indications because of its low risk of lymph node metastasis. 
A new endoscopic method, endoscopic submucosal dissec-
tion, has recently become available. This method allows en 
bloc resection without limitation of the size of the lesion. The 
goal of this article is to review the history and methods of en-
doscopic treatment with EGC, the conventional and extended 
indications, the therapeutic outcomes, and the complication 
rates. (Gut Liver 2011;5:418-426)
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INTRODUCTION
The incidence of gastric cancer has been decreasing for sev-
eral decades. Gastric  cancer has become a relatively rare cancer 
in North America and in most of Northern and Western Europe.
1 
However, gastric cancer remains the most common cancer 
worldwide with approximately 870,000 new cases and 650,000 
deaths per year.
2 In Korea, the age-adjusted annual incidence of 
gastric cancer per 100,000 persons is 62.8 for men and 25.7 for 
women.
3 The proportion of early gastric cancer (EGC) at diagno-
sis is increasing due to the use of mass screening endoscopy. In 
the past, the standard treatment of gastric cancer was surgical 
resection; however, the endoscopic treatment has increased due 
to advances in the instruments available and clinician experi-
ence.
4 Endoscopic mucosal resection (EMR) has been used as 
the first line treatment for EGC without evidence of lymph node 
(LN) metastasis. Evidence supports that EMR for EGC, without 
LN metastasis, has similar efficacy compared to open surgery.
5 
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Furthermore, as life expectancy has been extended because of 
improved quality of life and better treatment of chronic disease, 
many patients have one or more chronic diseases. For patients 
with co-morbidities, EMR is an alternative method without the 
same risk as open surgery due to the reduced invasiveness. A 
recent study demonstrated that there was no difference in the 
complication rate between high risk and low risk patients.
6 Thus, 
EMR may be a good alternative treatment choice for patients 
with co-morbid diseases. The goal of this article is to describe 
the history and the methods of endoscopic treatment of EGC, 
the indications, the points to consider with regard to extended 
indications, the therapeutic outcomes and complications.
HISTORY OF TECHNICAL DEVELOPMENT: FROM EMR 
TO ESD
In 1974, the first attempt of endoscopic treatment for polyp-
oid type gastric cancer was reported in Japan.
7 In 1984, the strip 
biopsy was described as a development of the endoscopic snare 
polypectomy;
8 this technique used a double channel endoscope. 
After submucosal injection around the lesion, a grasper was 
used to lift the lesion through one channel, and then a snare 
that was inserted through the other channel was used to resect 
the lesion. In 1988, another EMR technique (EMR after circum-
ferential pre-cutting, EMR-P) using hypertonic saline mixed 
with diluted epinephrine solution was introduced;
9 cutting 
around the lesion with a needle knife is done after hypertonic 
saline injection into the submucosal layer, and then the lesion 
is removed by a snare (Fig. 1). In 1992, the EMR using transpar-
ent cap (EMR-C) technique, was developed and used for early 
esophageal cancer and EGC.
10 This technique uses a transparent 
hood that is connected to the tip of a standard endoscope. After 
the submucosal injection, the lesion is sucked into the cap while 
a specialized crescent-shaped snare which is located at the tip of 
the cap is closed.Kang KJ, et al: Gastric Endoscopic Submucosal Dissection  419
Fig. 1. Standard endoscopic mucosal dissection (EMR) techniques. (A) EMR after circumferential pre-cutting (EMR-P). (B) Cap-fitted endoscopy 
(EMR-C).
Fig. 2. The endoscopic submucosal dissection (ESD) procedure. (A) On the anterior wall of the antrum, a 1.2-cm type IIa early gastric cancer is 
found. (B) Indigocarmine is sprayed along the extent of tumor to aid visualization. (C) Marking outside the lesion. (D) After injection of saline 
mixed with diluted epinephrine (1:100,000) and indigocarmine into the submucosal layer, circumferential mucosal pre-cutting is performed using 
a standard needle knife. (E) After dissection of the submucosal layer, a post-ESD induced ulcer is seen. (F) Fixation of the tissue specimen. 420  Gut and Liver, Vol. 5, No. 4, December 2011
After this, the EMR with ligation (EMR-L) was introduced.
11,12 
This technique uses a standard endoscopic variceal ligation de-
vice to capture the lesion. The EMR-C and the EMR-L are simple 
and effective methods for small cancers; however, it is unsuit-
able for lesions larger than 20 mm. Usefulness for en bloc resec-
tions is limited. 
In late 1990s, endoscopic submucosal dissection (ESD) 
method was developed and endoscopic treatment for EGC has 
been extended to lesions larger than 20 mm in size; after indi-
gocarmine spray, marking around the lesion is done by vari-
ous knives. Circumferential mucosal pre-cutting is performed 
using a standard needle knife after saline mixed with diluted 
epinephrine (1:100,000) and indigocarmine injection into the 
submucosal layer. Then, submucosal layer under the lesion is 
dissected with lateral movement using various knives (Fig. 2). 
Initially, ESD used an insulation-tipped (IT) diathermic knife 
for the submucosal dissection.
13,14 A variety of other endoscopic 
knives such as needle knife, hook knife, flex knife, triangle tip 
knife, flush knife, and splash knife and IT-2 knife have been de-
veloped and used (Fig. 3). 
Recently, ESD has evolved in endoscopic surgery. New in-
struments (magnetic anchor-guided ESD, springs, multitask 
devices, and double endoscopic intraluminal surgery) have been 
introduced and have begun to play a role in enabling excellent 
visualization of the submucosal layer.
15-17 These techniques have 
reduced some technical problems involved in the ESD proce-
dure. 
INDICATIONS FOR ENDOSCOPIC RESECTION FOR EGC
1. Conventional indications
The most important indications for endoscopic treatment of 
EGC are determined by considering the risk of LN metastasis 
and technical problems and whether to resect the tumor en bloc. 
The conventional criteria for endoscopic resection of EGC which 
was proposed by Japanese group are: 1) differentiated adeno-
carcinoma, 2) intramucosal cancer, 3) size of the lesion less than 
20 mm, 4) without any endoscopic findings of ulceration,
4,18 5) 
no LN involvement or metastasis by computed tomography. 
Lesions that meet all of the above mentioned criteria should be 
considered for en bloc resection by conventional EMR methods 
due to the low risk of LN metastasis.
2. Extended indications
Recently, based on surgical data, extended indications for 
EMR have been proposed (Table 1). After an analysis of the re-
Fig. 3. Different types of knives used 
for endoscopic submucosal dissec-
tion. (A) Insulation-tipped diather-
mic knife. (B) Hook knife. (C) Flex 
knife. (D) Dual knife.Kang KJ, et al: Gastric Endoscopic Submucosal Dissection  421
sults of 5,265 patients who underwent gastrectomy with LN dis-
section, Gotoda et al.
4,19 and An et al.
20 reported the lesion that 
meets these criteria has no or minimal risk of LN metastasis: 1) 
no size limitation for intramucosal differentiated cancers with-
out ulceration that have no lymphovascular invasion, 2) less 
than 3 cm in diameter for ulcerated differentiated intramucosal 
cancers without lymphovascular invasion, 3) less than 3 cm in 
diameter for differentiated cancers (extension into the submu-
cosal for less than 500 micrometers) without lymphovascular 
invasion, 4) less than 2 cm in diameter for undifferentiated in-
tramucosal cancers without ulceration. Currently, the extended 
criteria for ESD are in use in Japan.
However, there are several issues to consider with the ex-
tended indications. The first issue is the risk of LN metastasis. In 
a Korean study, 855 patients who underwent gastrectomy with 
LN dissection for EGC were analyzed; LN metastasis was identi-
fied in 4.7% (20/427) of mucosal cancers and 22.2% (95/428) of 
submucosal cancers. In the mucosal cancers that were less than 
10 mm in size, LN metastasis was detected in 2 cases.
21 In ad-
dition, among 2,173 patients who underwent gastrectomy with 
LNs dissection, LN metastasis was found in 4.5% (50/1,108) of 
mucosal cancers. Among the mucosal cancers, there was LN 
metastasis in 2 differentiated cancers without ulceration that 
were 21 to 40 mm in size, and 1 differentiated cancer with ul-
ceration, 21 to 30 mm in size (tumor size was not described).
22 
Although these results reflect only a small portion of mucosal 
cancers, the possibility of LN metastasis should be considered 
when the extended criteria are used for the treatment of EGC. 
The second issue is the histological discrepancy before and 
after endoscopic resection of gastric adenoma and EGC. Park 
et al.
23 reported that the discrepancy rate between the histology 
of the endoscopic biopsy and the resected specimen was 40.6% 
for the gastric adenoma and 23.7% for the EGC. Recently, of the 
293 lesions diagnosed as low grade gastric adenoma by forcep 
biopsy, 51 (18.7%). Histology was upgraded after endoscopic 
resection. They reported that absence of whitish discoloration 
was associated with significant factor influencing histologic 
discrepancies (p=0.001; odds ratio, 5.29; confidence interval, 
1.95 to 14.37).
24 In another study of low grade gastric adenoma 
diagnosed by forcep biopsy, 272 lesions (89.2%) were finally 
diagnosed as low grade adenoma and 33 lesions (10.8%) were 
diagnosed as having high grade foci, including 1 intramucosal 
carcinoma. they demonstrated that lesion size >1 cm on endos-
copy and finding of tubulovillous or villous histology on forcep 
biopsy specimens were independent risk factor for histologic 
discrepancy before and after endoscopic resection of low grade 
adenoma.
25 Thus, therapeutic endoscopists have to keep in mind 
about the possibility of histological discrepancy before and after 
endoscopic resection. 
The third issue is the differences in the pathological diagnosis 
of gastric adenocarcinoma and premalignant lesions between 
East and West: 1) The different concept of gastric adenoma 
and dysplasia. In Western countries, gastric dysplasia is di-
vided into flat/depressed dysplasia and elevated dysplasia. Only 
an elevated dysplasia is called adenoma. In Eastern countries 
(mainly Japan and including Korea), the terms “dysplasia” and 
“adenoma” are both used for non-invasive neoplastic lesion 
regardless of tumor shape (protruded, flat, depressed, etc.).
26 2) 
Difference in diagnostic criteria for gastric carcinoma. Western 
pathologists consider invasion into the lamina propria of the 
mucosa mandatory for the diagnosis of carcinoma, whereas 
nuclear and structural features are much important for the 
Japanese pathologists. Western pathologists diagnose as low- or 
high-grade dysplasia in cases diagnosed as well differentiated 
carcinoma by Japanese pathologists.
27 3) Japanese classification 
of differentiated adenocarcinoma with high grade atypia and 
low grade atypia. Japanese pathologists have divided differenti-
ated gastrointestinal adenocarcinoma into low-grade atypia and 
high-grade atypia.
28 Western and Korean pathologists, generally 
do not use the Japanese sub-classification of gastric adenocar-
cinoma. As mentioned above, standardization of terms and di-
agnostic criteria to reduce the discrepancy in diagnosis between 
the East and West are needed. 
The fourth issue is the histological heterogeneity in sub-
mucosal invasive differentiated type gastric adenocarcinoma. 
Histologically, gastric carcinoma is generally classified into dif-
ferentiated and undifferentiated type or intestinal and diffuse 
type. These types are based on morphological features and his-
tological backgrounds.
29,30 Several reports showed that a large 
portion of gastric cancers had histological mixed cancers (dif-
ferentiated and undifferentiated type).
31,32 Mita and Shimoda
33 
reported that the rate of LN metastasis was significantly higher 
Table 1. Criteria for Expanded Endoscopic Resection in Patients with Early Gastric Cancer
Mucosal cancer Submucosal cancer
Ulcer (-) Ulcer (+) Sm1  Sm2 
Size, mm ≤20 >20 ≤30 >30 ≤30 Any size
Differentiated cancer A B B D B D
Undifferentiated cancer C D D D D D
Data from Soetikno et al. J Clin Oncol 2005;23:4490-4498.
53
A, classic indications; B, expanded indications; C, surgery, but need for further consideration; D, surgery. 422  Gut and Liver, Vol. 5, No. 4, December 2011
in differentiated submucosal cancer with histological heteroge-
neity (combined differentiated type, with poorly differentiated 
component) than in that without histological heterogeneity (27% 
vs 7%, p<0.001). It is recommended to be applied to the differ-
entiated submucosal cancer without histological heterogeneity 
when endoscopic resection in differentiated submucosal cancer 
is considered. Thus, we have to focus on the histological mixed 
cancer due to increased risk of LN metastasis in case with sub-
mucosal invasion.  
The fifth issue is the endoscopic treatment of undifferenti-
ated cancer; the risk of LN metastasis is significantly increased 
in these cases, due to lymphovascular invasion.
34 Recently, 310 
undifferentiated cancers without ulceration were analyzed in 
Japan. There was no LN metastasis in the tumors without lym-
phovascular invasion and the sizes were less than 20 mm.
35 In 
Korean research, one study demonstrated that poorly differenti-
ated mucosal cancer or minimal submucosal infiltration (≤500 
μm) was reported as acceptable for curative endoscopic resec-
tion due to the low risk of lymphovascular invasion.
36 Another 
study reported that signet ring cell EGC was more appropriate 
for endoscopic treatment than poorly differentiated EGC because 
the latter was significantly associated with ulcers, submucosal 
invasion, and lymphovascular invasion with reference to signet 
ring cell EGC. Additionally, youth was viewed as an indepen-
dent risk factor for LN metastasis only in poorly differentiated 
EGC;
37 however, the results require further study confirmation 
due to the small sample size.  
For the expansion of the criteria for endoscopic submucosal 
treatment of EGC, confirmation of no difference in the long 
term survival data between endoscopic treatment and conven-
tional surgery is needed. Thus, large, prospective studies of ESD 
are needed to address such issues.  
TREATMENT OUTCOMES
The disease-specific 5- and 10-year survival rates of EMR are 
both 99% for  differentiated mucosal cancers of less than 2 cm 
in size.
5 Currently, EMR for EGC is the standard initial treatment 
for EGC in patients that meet the conventional indications.
38 In 
Japan, the EMR outcome for EGC, the rates of en bloc resection, 
complete resection, recurrence rate, and disease free survival 
have been reported to be 75.8%, 73.9%, 1.9%, and 99.1%, re-
spectively. For the Korean multicenter study of EMR for EGC, 
514 EGCs in 506 patients were treated by EMR. The most com-
monly used techniques have been circumferential precutting 
followed by snare resection (EMR-P, 52.3%). The rate of en bloc 
resection and complete resection were 71.8% and 77.6%, re-
spectively. Tumor size was associated with the rate of complete 
resection. The rate of complete resection for lesions with diame-
ter of 3 cm or less was 80.2%, whereas the rate for lesions larger 
than 3 cm was 56.4%. For completely resected mucosal cancers, 
the median duration of follow-up was 23.5 months (range, 5 to 
70 months). In this group, the rate of local recurrence, perfora-
tion, and bleeding were 6%, 0.6%, and 13.8%, respectively.
39
The risk of local recurrence after EMR depends on the number 
of resected specimens. In Japan, the recurrence rate after EMR 
was 2% to 37%.
40 When the number of resected specimens was 
up to 2 samples, the recurrence rate was within 10%. However, 
it increased to above 20% when the resected specimens included 
three samples. In other study, significant factor of local recur-
rence after EMR was a macroscopic finding, especially in case 
with ulcer finding, the rate of recurrence was 50% which was 
higher than for other types.
39
The introduction of ESD could increase the en bloc resection 
rate. The outcomes of ESD showed ≥95% en bloc resection rate 
and about a 90% complete resection rate in several studies.
41,42 
In a Korean multicenter study of ESD, the rate of en bloc re-
section and complete resection was reported to be 95.3% and 
87.7%, respectively. The rates of delayed bleeding, significant 
bleeding, and perforation were 15.6%, 0.6%, and 1.2%, respec-
tively. the rates of en bloc resection was significantly associated 
with the location of the lesions, presence of a scar, and histo-
logic type (Table 2).
43 Recently, the outcome of patients with 
EGC which fulfilled the expanded indication was reported in 
Japan.
44 In this study, ESD was performed for patients with EGC 
(mucosal cancer without ulcer findings irrespective of tumor 
size; mucosal cancer with ulcer findings ≤3 cm in size). A total 
of 559 EGC lesions were enrolled and the median follow-up 
period was 30 months (range, 6 to 89 months). The rate of en 
bloc resection and curative resection was 94.9% and 94.7%, re-
spectively. The 5-year overall and disease-specific survival rates 
were 97.1% and 100%, respectively. The survival outcome of 
ESD in expanded indication was likely to be excellent, though 
long term survival outcome remains to be established by a large 
Table 2. Factors for En Bloc Resection of ESD for Early Gastric Neo-
plasms 
The rates of en bloc 
resection
Location
   Upper body     62/70 (88.6)
   Mid body 200/210 (95.2)
   Lower body 691/720 (96.0)
Presence of scar
   Yes 102/114 (89.5)
   No 851/886 (89.5)
Histologic type 
   Low grade adenoma 250/261 (95.8)
   High grade adenoma 194/205 (94.6)
   Differentiated early gastric cancer 478/497 (96.2)
   Undifferentiated early gastric cancer    31/37 (83.8)
Data from Chung et al. Gastrointest Endosc 2009;69:1228-1235.
43
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prospective study.
A phase II study of ESD with extended indications for EGC 
has been started in Korea to evaluate the safety and efficacy of 
ESD for EGC. This study will collect data on the 5-year survival 
rate, overall survival in cases without ulcerated lesions, overall 
survival in cases with ulcerated lesions, the recurrence-free sur-
vival, 5-year recurrence-free survival, adverse events and seri-
ous adverse events.
45
COMPLICATIONS ASSOCIATED WITH ENDOSCOPIC RE-
SECTION
The common complications of ESD are pain, bleeding, and 
perforation. The pain after endoscopic resection is generally 
mild and easily controlled by proton pump inhibitors and opi-
oids. Bleeding is the most common complication and is divided 
into immediate and delayed bleeding. Immediate bleeding dur-
ing the procedure frequently occurs with the resection of tumors 
located in the upper third of the stomach because the blood 
Fig. 4. Bleeding during the endoscopic submucosal dissection procedure. (A) Type IIb early gastric cancer on the high body. (B) Dissection of the 
submucosal layer. (C) Arterial bleeding from the submucosal layer.
Fig. 5. Perforation during the endoscopic submucosal dissection (ESD) procedure. (A) Type IIb early gastric cancer on the lower body. (B) Ulcer 
after ESD procedure. (C, D) Frank perforation of the ulcer bed. (E) Endoscopic closure with clips. (F) Free air on the chest X-ray.424  Gut and Liver, Vol. 5, No. 4, December 2011
supply is good and many large vessels are located in the body 
of the stomach (Fig. 4). The rate of bleeding after ESD has been 
reported to range from 1.8% to 15.6% in Korea.
43,46,47 Delayed 
bleeding is defined as hematemesis or melena at 0 to 30 days 
after the procedure. In a Korean multicenter study of ESD, de-
layed bleeding was related to the location (upper portion) and 
size of the tumor (>40 mm), recurrent lesions, and the macro-
scopic type (flat lesion).
43
Perforation is less common compared to bleeding. The per-
foration risk is about 1% to 4% during an ESD procedure.
48 
Perforations are divided into micro-perforation and frank per-
foration by the endoscopic findings, as well as immediate and 
delayed perforations based on the time of occurrence. Generally, 
a perforation of the stomach is conservatively managed without 
surgery after closing it with endoclips; this is because the stom-
ach during endoscopic resection is considered clean due to fast-
ing and gastric acid, which have antibacterial effects (Fig. 5).
49,50 
If a severe pneumoperitoneum develops due to a perforation, 
decompression of the pneumoperitoneum must be performed 
using a 14-G puncture needle to prevent the deterioration of 
breathing and/or neurogenic shock.
51
Minor complications that occur with ESD include stricture 
and aspiration pneumonia. Strictures frequently occur at the 
cardia and pylorus, especially with lesions around 1 cm at the 
gastroesophageal junction and pylorus, 3/4 circumferential 
resection of the lumen and/or longitudinal dissection of more 
than 5 cm in size; they are successfully treated by balloon 
dilatation.
52 The endoscopist should explain the possibility of a 
stricture to patients with risk factors before performing the ESD. 
In patients of advanced age, aspiration pneumonia can occur 
after an ESD; frequent removal of gastric fluid helps prevent 
pneumonia and avoid over distention during the ESD. 
CONCLUSIONS
EMR is currently considered the standard initial treatment for 
EGC in cases that meet the conventional indications. This pro-
cedure provides patients with a good quality of life and there is 
also a cost benefit for EGC treatment compared to conventional 
surgery. The improvement of endoscopic skills with advanced 
and endoscopic instruments has resulted in a new technique, 
ESD. ESD is better than the EMR for the removal of large le-
sions. However, the technical difficulty requires a long learn-
ing period and the technical invasiveness increases the risk of 
bleeding and perforation. Recently, new technical approaches 
(magnetic anchor-guided ESD, springs, multitask devices, and 
double endoscopic intraluminal surgery) have evolved in ESD 
and are making ESD a more efficient and less time-consuming 
procedure.
Additional studies of ESD are needed to evaluate the extended 
indications with regard to efficacy, standard diagnosis and ter-
minology and long term outcome. ESD may become a standard 
procedure for patients with EGC in cases that meet the extended 
indications; however, confirmation of the long term outcomes 
and appropriate indications for the procedure are needed.  
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